Literature DB >> 19764985

JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.

Vahid Asnafi, Sandrine Le Noir, Ludovic Lhermitte, Claude Gardin, Faézeh Legrand, Xavier Vallantin, Jean-Valère Malfuson, Norbert Ifrah, Hervé Dombret, Elizabeth Macintyre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19764985     DOI： 10.1111/j.1365-2141.2009.07912.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  27 in total

1.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

2.  Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.

Authors:  Kirsten Canté-Barrett; Joost C M Uitdehaag; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 3.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 4.  The molecular basis of T cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Adolfo Ferrando
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

Review 6.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

7.  Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways.

Authors:  Sheryl M Gough; Liat Goldberg; Marbin Pineda; Robert L Walker; Yuelin J Zhu; Sven Bilke; Yang Jo Chung; Joseph Dufraine; Subhadip Kundu; Elad Jacoby; Terry J Fry; Susanna Fischer; Renate Panzer-Grümayer; Paul S Meltzer; Peter D Aplan
Journal:  Blood Adv       Date:  2017-09-08

8.  RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.

Authors:  Valentina Gianfelici; Sabina Chiaretti; Sofie Demeyer; Filomena Di Giacomo; Monica Messina; Roberta La Starza; Nadia Peragine; Francesca Paoloni; Ellen Geerdens; Valentina Pierini; Loredana Elia; Marco Mancini; Maria Stefania De Propris; Valerio Apicella; Gianluca Gaidano; Anna Maria Testi; Antonella Vitale; Marco Vignetti; Cristina Mecucci; Anna Guarini; Jan Cools; Robin Foà
Journal:  Haematologica       Date:  2016-05-05       Impact factor: 9.941

Review 9.  Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

Authors:  Mahsa Mohseni; Hasan Uludag; Joseph M Brandwein
Journal:  Am J Blood Res       Date:  2018-12-10

10.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.